May 19th 2025
The FDA previously approved Jivi in 2018 to treat adults aged 12 years and older with hemophilia A.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens
Exploring Therapeutic Advances in Myelofibrosis and Key Considerations for Effective Management
NSAIDs May Be Safe for Use in Hemophilia, but More Research Is Needed